FreeStyle Libre
FreeStyle Libre is Abbott's flagship continuous glucose monitoring product line, offering factory-calibrated 15-day sensors and a connected app ecosystem for people with Type 1, Type 2, and gestational diabetes across all ages (2+) in the US.
- Company typePublic
- Founded-
- HeadquartersAlameda, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What FreeStyle Libre does
FreeStyle Libre is a continuous glucose monitoring (CGM) product line developed and marketed by Abbott Diabetes Care, Inc., a subsidiary of Abbott Laboratories (NYSE: ABT). The portfolio centers on factory-calibrated 15-day wearable sensors — the FreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus — worn on the back of the upper arm that measure interstitial glucose and stream minute-by-minute readings to a unified Libre smartphone app without requiring fingerstick calibration. Around the sensor sits a software ecosystem: LibreView for cloud-based historical data review by healthcare providers, LibreLinkUp for sharing glucose readings with up to 10–20 family members and caregivers, and a generative AI feature called Libre Assist that predicts the glucose impact of photographed meals and recommends lower-impact food choices. FreeStyle Libre is the only CGM that integrates with all four leading automated insulin delivery systems in the US (Omnipod 5, Tandem t:slim X2, iLet Bionic Pancreas, and twiist), positioning it as the default sensor for hybrid closed-loop pump patients.
The product line serves people with Type 1, insulin-treated Type 2, and gestational diabetes across all ages from 2 and up, including Medicare, Medicaid, VA, and TRICARE beneficiaries. FreeStyle Libre holds the #1 prescribed CGM position in the US and is described as the most connected CGM worldwide, with over 95% of private insurance plans providing coverage and most covered patients paying $0–$20 for sensors. Distribution runs through retail pharmacies, durable medical equipment (DME) suppliers, mail order, and government pharmacies, with a dedicated customer care team and the MyFreeStyle direct-to-patient free trial program supporting acquisition.
Revenue is generated primarily through disposable sensor hardware sales at high volume through prescription-based fulfillment channels, with a recurring consumable economics profile (sensors replaced every 15 days). The go-to-market is sales-led via healthcare provider prescriptions, layered with direct-to-consumer touchpoints including the MyFreeStyle program, a copay savings card for commercially insured and uninsured patients, and dedicated support lines. FreeStyle Libre is not separately listed; standalone revenue is not disclosed and the business is reported within Abbott's Diabetes Care segment.
FreeStyle Libre firmographics
Firmographics- Name
- FreeStyle Libre
- Legal name
- Abbott Diabetes Care, Inc.
- Website
- https://freestyle.abbott
- Company type
- Public
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- FreeStyle Libre is Abbott's flagship continuous glucose monitoring product line, offering factory-calibrated 15-day sensors and a connected app ecosystem for people with Type 1, Type 2, and gestational diabetes across all ages (2+) in the US.
- Ownership category
- akta.pro rank
FreeStyle Libre industry classification
Industry- Product category
- Continuous Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
- akta.pro secondary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
Keywords
Where FreeStyle Libre is headquartered
LocationHeadquarters
- HQ city
- Alameda
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
FreeStyle Libre business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel
Revenue model
- Sensor Sales: Primary revenue from disposable glucose sensors (FreeStyle Libre 2 Plus and 3 Plus) worn for 15 days. Sensors are sold through retail pharmacies, DME suppliers, and mail order with prescription requirement. Most covered patients pay $0-$20 through insurance.
- Reader/Device Sales: FreeStyle Libre readers and the Libre app provide device interface for sensor data. Readers sold separately or as part of initial system purchase. Medicare Part B covers as durable medical equipment (DME).
- Insurance/Payor Contracts: Revenue generated through coverage agreements with private insurance (>95% of plans), Medicare, Medicaid, VA, and TRICARE. Covered as DME under Medicare Part B for eligible patients managing diabetes with insulin or having problematic hypoglycemia.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Standard Sensor Pricing (Insured) |
| Hybrid | Pay-as-you-go | Copay Savings Program |
| Freemium | One time/ perpetual license | Free Trial Program (MyFreeStyle) |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels7 records
FreeStyle Libre product offering
Product offeringCore offering
FreeStyle Libre manufactures and sells continuous glucose monitoring (CGM) systems consisting of factory-calibrated, 15-day wearable sensors that measure interstitial glucose and transmit real-time readings every minute to the Libre smartphone app. The portfolio includes the FreeStyle Libre 3 Plus and Libre 2 Plus sensors, the unified Libre mobile app, LibreView cloud software for healthcare provider data review, and LibreLinkUp for caregiver notifications. The sensors are compatible with all leading automated insulin delivery systems in the U.S. and are prescribed for individuals with Type 1, Type 2, and gestational diabetes ages 2 and older.
Product overview
FreeStyle Libre is a continuous glucose monitoring (CGM) system portfolio by Abbott Diabetes Care for people with diabetes. The product line centers on wearable sensors (FreeStyle Libre 3 Plus, Libre 2 Plus, and legacy models) that measure glucose levels continuously and transmit data to the Libre smartphone app every minute. The ecosystem includes LibreView for healthcare provider data analysis, LibreLinkUp for caregiver sharing, and integrations with major automated insulin delivery systems (Omnipod 5, Tandem t:slim X2, iLet Bionic Pancreas, twiist). The Libre Assist AI feature provides personalized food impact predictions. FreeStyle Libre 3 Plus and Libre 2 Plus are the latest 15-day sensors, succeeding older 14-day models being discontinued.
Differentiator
Problem solved
Functional benefit
Brands
- FreeStyle Libre 3 Plus: Latest generation 15-day CGM sensor with real-time glucose readings, compatible with automated insulin delivery systems.
- FreeStyle Libre 2 Plus
- FreeStyle Libre 3
- FreeStyle Libre 2
- Libre app
- LibreView
- LibreLinkUp
- Libre Assist
- MyFreeStyle
Products and services
- FreeStyle Libre 3 Plus Sensor The flagship 15-day continuous glucose monitoring sensor with real-time glucose readings every minute, described as the world's smallest sensor, worn discreetly on the back of the upper arm and compatible with all leading U.S. insulin pump brands. Indicated for ages 2 and older.
- FreeStyle Libre 2 Plus Sensor A 15-day CGM sensor with optional glucose alarms within 20 feet (unobstructed) and compatibility with automated insulin delivery systems. Indicated for ages 2 and older.
- FreeStyle Libre 3 Sensor Real-time CGM sensor that transmits automatic glucose readings every minute to the Libre app. The predecessor to the FreeStyle Libre 3 Plus, now being phased out.
- FreeStyle Libre 2 Sensor CGM sensor with optional high/low glucose alarms. The predecessor to the FreeStyle Libre 2 Plus, now being phased out.
- FreeStyle Libre 14 Day Sensor Original 14-day flash glucose monitoring system requiring users to scan the sensor to obtain readings. Indicated for adults aged 18 and older.
- Libre App Unified mobile application compatible with all FreeStyle Libre sensors (Libre 2, Libre 2 Plus, Libre 3, and Libre 3 Plus) on iOS and Android. Provides real-time glucose readings, customizable alarms, the Libre Assist AI food-impact feature, and integration with LibreView and LibreLinkUp.
- FreeStyle Libre Reader Handheld device for scanning FreeStyle Libre sensors and viewing glucose readings. Being phased out in favor of the Libre smartphone app.
- LibreView Cloud-based data management software that allows patients and healthcare providers to review, analyze, and evaluate historical glucose data to support diabetes management decisions. Requires registration.
- LibreLinkUp Mobile application that allows FreeStyle Libre users to share their glucose readings and alerts with family members, friends, and caregivers. Requires LibreView registration and internet connectivity.
Quantifiable outcome
- Sustained A1C reductions for up to 24 months
- +4 more outcomes
Companies that use FreeStyle Libre
Customer profileNamed customers2 records
Segments6 records
Ideal customer profiles5 records
FreeStyle Libre technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration13 records
AI capability4 records
Feature5 records
FreeStyle Libre partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Omnipod (Insulet Corporation)coreOmnipod 5 is a tubeless, waterproof automated insulin delivery system that works with FreeStyle Libre 3 Plus sensor. SmartAdjust technology proactively predicts glucose values 60 minutes ahead to correct highs and protect against lows. Caregivers can set and receive glucose alarms through LibreLinkUp app.
- Tandem Diabetes Carecoret:slim X2 insulin pump powered by Control-IQ+ technology uses FreeStyle Libre 3 Plus sensor values to predict glucose levels 30 minutes ahead and automatically adjust insulin. Only Tandem pumps have AutoBolus for missed meal boluses. Users can share CGM data with up to 20 family members/caregivers via Sugarmate by Tandem app.
- Beta BionicscoreiLet Bionic Pancreas is an automated insulin delivery system that makes 100% of dosing decisions, requiring no carb counting. Paired with FreeStyle Libre 3 Plus sensor, it constantly learns and adapts to insulin needs. Users share glucose and insulin data with up to 10 family members via Bionic Circle app.
- twiist (Tidepool)coretwiist AID System powered by Tidepool creates an integrated experience with FreeStyle Libre 3 Plus sensor. Automatic readings are sent every minute from sensor to pump. Parents and caregivers can see glucose and insulin data through twiist insiight app.
- WeightWatchers (WW)minorWeightWatchers x Abbott connected experience allows FreeStyle Libre CGM data sharing into WW app for people living with diabetes. Users learn how food and activity impact glucose levels, guided by WW Diabetes-Tailored Plan to make healthier choices and lower A1C.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
FreeStyle Libre competitors and assessment
Company assessmentEmerging players
- Beta Bionics: Beta Bionics' iLet Bionic Pancreas is a newer AID system paired with FreeStyle Libre 3 Plus. It is an emerging player in automated insulin delivery with overlapping diabetes-management scope.
- Senseonics Holdings: Senseonics markets the Eversense implantable CGM, a differentiated long-wear CGM approach. It is a smaller emerging player competing in the same CGM category with a distinct technology profile.
Regional players
- Ascensia Diabetes Care: Ascensia distributes the Contour blood glucose monitoring portfolio and is exploring CGM adjacencies. It competes in diabetes management broadly but is not a direct CGM pure-play comparable to FreeStyle Libre.
Broad incumbents
- LifeScan (Metron/Platinum Equity): LifeScan markets traditional blood glucose meters and is repositioning toward digital and CGM-adjacent offerings. It overlaps with FreeStyle Libre in diabetes monitoring infrastructure but is not a CGM direct competitor.
- Roche Diabetes Care: Roche is a broad incumbent with traditional blood glucose monitoring and insulin delivery offerings. It overlaps with FreeStyle Libre in diabetes management but does not compete directly as a CGM specialist.
- Medtronic Diabetes: Medtronic sells the Guardian CGM system alongside its insulin pumps as part of a broader diabetes portfolio. It is a broad incumbent competitor with overlapping CGM-and-pump offerings rather than a CGM pure-play.
Others
- Insulet Corporation (Omnipod): Insulet is a strategic pump partner integrated with FreeStyle Libre 3 Plus via the Omnipod 5 AID system. It is an ecosystem participant rather than a direct CGM competitor, but its commercial success is coupled to FreeStyle Libre's sensor performance.
- Tidepool: Tidepool powers the twiist AID system that integrates with FreeStyle Libre 3 Plus. It is an enabling software/digital-health partner in the FreeStyle Libre diabetes ecosystem rather than a competing CGM.
- Tandem Diabetes Care: Tandem's t:slim X2 pump integrates with FreeStyle Libre 3 Plus via Control-IQ+ technology. Like Insulet, Tandem is a partner in the AID ecosystem that depends on FreeStyle Libre for the CGM data feed.
Direct peers
- Dexcom: Dexcom is the principal direct competitor in CGM, offering the G7 sensor and competing head-to-head with FreeStyle Libre in insulin-using Type 1 and Type 2 patients. FreeStyle Libre marketing copy repeatedly benchmarks pricing and integration against Dexcom.
Market position
Strengths2 records
Weaknesses5 records
Competitive moat7 records
Key risks5 records
Key highlights7 records
Customer concentration
FreeStyle Libre social profiles
Digital presenceFreeStyle Libre financial estimates
Financial estimateRevenue estimate
Valuation estimate
FreeStyle Libre leadership team
Management profileNumber of profiles
FreeStyle Libre funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FreeStyle Libre M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FreeStyle Libre
What does FreeStyle Libre do?
FreeStyle Libre manufactures and sells continuous glucose monitoring (CGM) systems consisting of factory-calibrated, 15-day wearable sensors that measure interstitial glucose and transmit real-time readings every minute to the Libre smartphone app. The portfolio includes the FreeStyle Libre 3 Plus and Libre 2 Plus sensors, the unified Libre mobile app, LibreView cloud software for healthcare provider data review, and LibreLinkUp for caregiver notifications. The sensors are compatible with all leading automated insulin delivery systems in the U.S. and are prescribed for individuals with Type 1, Type 2, and gestational diabetes ages 2 and older.
Is FreeStyle Libre a public or private company?
FreeStyle Libre is a public company. It is classified as corporate owned and is currently operating.
When was FreeStyle Libre founded?
FreeStyle Libre was founded in -1. It employs 1 to 10 people.
Where is FreeStyle Libre based?
FreeStyle Libre is headquartered in Alameda, United States, in the North America region.
How does FreeStyle Libre make money?
Three revenue lines are on record. Sensor Sales are the primary driver. The others are reader/Device Sales and insurance/Payor Contracts.
Who are FreeStyle Libre's main competitors?
Emerging players on record are Beta Bionics and Senseonics Holdings. Ascensia Diabetes Care is listed as a regional player. Broad incumbents are LifeScan (Metron/Platinum Equity), Roche Diabetes Care and Medtronic Diabetes. Others are Insulet Corporation (Omnipod), Tidepool and Tandem Diabetes Care. Dexcom is listed as a direct peer.
Does FreeStyle Libre have an API?
No public API is recorded for FreeStyle Libre.
What industry is FreeStyle Libre in?
FreeStyle Libre's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 334510 and its SIC code is 3845.